Incyte Reports 2019 Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical Programs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Incyte Reports 2019 Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical Programs

Incyte (INCY) Tops Q4 EPS by 8c, Revenues Beat

February 13, 2020 7:07 AM EST

Incyte (NASDAQ: INCY) reported Q4 EPS of $0.65, $0.08 better than the analyst estimate of $0.57. Revenue for the quarter came in at $579.39 million versus the consensus estimate of $575.6 million.

Total product and royalty revenues of $579 million (+24%) in 4Q 2019 and $2.1 billion (+22%) for the full year 2019; Jakafi® (ruxolitinib) revenues of $466 million (+23%) in 4Q... More